Fred Hutch Cancer Center researchers will present the latest findings on advancing treatments for blood, skin and breast cancers, as well as palliative care, financial toxicity and more at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
Follow Fred Hutch at ASCO: #ASCO26 | Facebook | Twitter | Bluesky
Date:
Friday-Tuesday, May 29-June 02, 2026
Host or Sponsor:
Contact Information:
Featured Oral Sessions
Nancy Davidson, MD, FASCO
Opening Session: David Karnofsky Science of Oncology Award Lecture
Date & Time: May 30, 2026, 11:25 – 11:45 a.m. CDT
Location: Hall B1
Evan Hall, MD, Mphil
Rapid Oral Session: MATRIX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti PD-(L)-1 refractory Merkel cell carcinoma
Date & Time: May 30, 2026, 4:42 – 4:48 p.m. CDT
Location: E451
Hemant Khandelia, MBBS
Rapid Oral Session: Response-focused analyses of the impact of circadian rhythm on efficacy of first-line immunotherapy in melanoma
Date & Time: May 30, 2026, 5:42 – 5:48 p.m. CDT
Location: E451
Poster #234b: Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced or metastatic pancreatic adenocarcinoma
Presenter: E. Gabriela Chiorean, MD, FASCO
Date & Time: May 30, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #179: Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial
Presenter: Eric Collisson, MD
Date & Time: May 30, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #298: Impact of broadening trial eligibility criteria on the inclusion of patients infected with HIV in cancer clinical trials
Presenter: Joseph Unger, PhD
Date & Time: May 30, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #306: Geographic distribution of cancer treatment trials and population-level cancer outcomes in the US
Presenter: Joseph Unger, PhD
Date & Time: May 30, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #1: Cardiovascular disease in women with early-onset breast cancer
Presenter: Vidhya Nair, DO
Date & Time: May 30, 2026, 1:30 p.m. – 4:30 p.m. CDT
Location: Hall A
Poster #126: A risk prediction model for severe, life-threatening, and fatal treatment-related toxicity
Presenter: Joseph Unger, PhD
Date & Time: May 30, 2026, 1:30 p.m. – 4:30 p.m. CDT
Location: Hall A
Poster #483: Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without lung and/or liver metastases
Presenter: Megan Othus, PhD
Date & Time: May 30, 2026, 1:30 p.m. – 4:30 p.m. CDT
Location: Hall A
Poster #446: Low-dose nivolumab in patients at high risk of immune-related adverse events
Presenter: Lisa Tachiki, MD
Date & Time: May 30, 2026, 1:30 p.m. – 4:30 p.m. CDT
Location: Hall A
Oncology Division Chiefs and Department Chairs Breakfast
Funding the future of academic oncology: challenges, opportunities, and successful tactics
Presenter: Thomas J. Lynch, MD
Date & Time: May 30, 2026, 7:45 – 8:10 a.m. CDT
Location: S501abc
Poster #136: Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer
Presenter: Ethan Lo, BS
Date & Time: May 31, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #47: Avelumab + sacituzumab govitecan vs avelumab monotherapy as first-line maintenance treatment for advanced urothelial carcinoma
Presenter: Petros Grivas, MD, PhD, FASCO
Date & Time: May 31, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #362: Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitors in non-small cell lung cancer
Presenter: Diane Tseng, MD, PhD
Date & Time: May 31, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #420: Hi-C sequencing to identify clinically actionable fusions in non-small cell lung cancer
Presenter: Kevin Max Levine, MD, PhD
Date & Time: May 31, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #422: Actionable genomic alterations and outcomes in lung squamous and adenosquamous cell carcinoma
Presenter: Simone Dekker, MD, PhD
Date & Time: May 31, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #165: Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC.
Presenter: Hiba Khan, MD, MPH
Date & Time: May 31, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #32: Baseline financial and credit status of participants enrolled in SWOG S1912CD
Presenter: Veena Shankaran, MD, MS
Date & Time: June 1, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #20: Decline in credit score and excess mortality risk among cancer patients
Presenter: Scott Ramsey, MD, PhD
Date & Time: June 1, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #524: Outcomes of lisocabtagene maraleucel in relapsed or refractory mantle cell lymphoma
Presenter: Jennifer Huang, MD, PhD
Date & Time: June 1, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #544: Subsequent therapies and PFS2 in treatment-naïve CLL/SLL previously treated in SEQUOIA
Presenter: Mazyar Shadman, MD, MPH
Date & Time: June 1, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #596a: Sonrotoclax + zanubrutinib vs venetoclax + acalabrutinib in treatment-naïve CLL
Presenter: Mazyar Shadman, MD, MPH
Date & Time: June 1, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #328: Phase II DA-EPOCH ± rituximab + tafasitamab in newly diagnosed Ph- B-ALL
Presenter: Noam Edward Kopmar, MD
Date & Time: June 1, 2026, 9:00 a.m. – 12:00 p.m. CDT
Location: Hall A
Poster #571: Initial findings from the PROMISE registry, a US decentralized prostate cancer genetic registry
Presenter: Heather Cheng, MD, PhD
Date & Time: June 1, 2026, 1:30 p.m. – 4:30 p.m. CDT
Location: Hall A
